| Literature DB >> 30813157 |
Samantha Mason1, Laura Castilla-Vallmanya2, Con James3, P Ian Andrews4, Susana Balcells2, Daniel Grinberg2, Edwin P Kirk1,5,6, Roser Urreizti2.
Abstract
RATIONALE: Trio family-based whole exome sequencing (WES) is a powerful tool in the diagnosis of rare neurodevelopmental diseases, even in patients with the unclear diagnosis. There have been previous reports of variants in the phosphatidylinositol glycan anchor biosynthesis class T (PIGT) gene associated with multiple congenital anomalies, with a total of 14 affected individuals across 8 families. PATIENT CONCERNS: An 18-month-old boy of Greek ancestry presented with global developmental delay, generalized tonic-clonic seizures, hypotonia, renal cysts, esotropia, bilateral undescended testes, bilateral vesicoureteric reflux, marked cardiac dextroposition, bilateral talipes equinovarus, and dysmorphic features. DIAGNOSIS: WES revealed 2 compound heterozygous variants in the PIGT gene, c.[494-2A>G]; [547A>C]/p.[Asp122Glyfs*35]; [Thr183Pro]. The splicing mutation was demonstrated to lead to the skipping of exon 4.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30813157 PMCID: PMC6407924 DOI: 10.1097/MD.0000000000014524
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Figure 1Most relevant features of the current patient. (A) Facies at 6 days of life. (B and C) Facies at 18 mo old. Note cupid's bow lips, full lower lip, posteriorly rotated ears, and a prominent premaxilla. (C) Deep plantar creases. (E) Small feet, third toes proximally inserted and bilateral 2-3 toe syndactyly. (F) Hand, with broad fingers and relatively large palms.
Description of clinical features observed in patients with PIGT variations.
Figure 2(A) PIGT gene representation (ENSG00000124155). The black arrow marks the position of the mutation (at exon 4 splicing acceptor site). (B) Schematic representation of the PIGT alternative transcripts and putative splicing events. (C) PCR amplification of the cDNA of the patient cells (P), the patient cells treated with Cycloheximide (P + Cx) and the control cells (WT). Mk: 100 pb molecular weight marker, (C−) PCR negative control. cDNA = complementary DNA, PCR = polymerase chain reaction, PIGT = phosphatidylinositol glycan anchor biosynthesis class T.